Anglonordic is the only life science conference in the UK that is exclusively for European investors and R&D companies from the Nordics and the UK to connect with each other. With an established format of panel discussions, parallel technology and biotech investment rooms, plus 1:1 meetings, this 1-day London conference provides exceptional value. Investors with funds attend free-of-charge.
MEET decision makers at leading and upcoming drug discovery and technology companies from the UK and Nordic regions, along with investment firms from throughout Europe
LEARN from major investment firms about the current status of European investment in life science technologies
GAIN insights from experienced life science operators within the Anglo-Nordic space
The Anglonordic Life Science Conference has a “by-invitation-only” policy. The organisers welcome a limited number of service suppliers as sponsors or exhibitors.
The main conference room has a biotech investment focus; the technology room features devices, diagnostics, delivery and development tools. One-to-one meetings take place throughout the day. The Exhibition and quiet area double up for lunch service and refreshments are available all day.
One-to-one partnering meetings are pre-booked using the globally-renowned Meeting Mojo booking platform. Registered delegates can log in to browse profiles, set their own availability, request meetings, and promote their company to best advantage.
Networking begins on the evening before the conference with an exclusive Reception in Central London, free of charge to all registered delegates.
Applications for presentation slots are being accepted by emailing firstname.lastname@example.org. DO NOT register here for delegate, sponsor, or exhibitor passes - instead follow the link in your invitation or request an invitation here.
Gold and Partnering Sponsors
Attendees at the 2018 event included companies from: Denmark, Finland, Germany, Luxembourg, Netherlands, Norway, Spain, Sweden, Switzerland, United Kingdom, and USA.
Organisations registered to attend include:
Investors: 4BIO Capital, Abingworth, Albion Technology & General VCT, Arix Bioscience, Axilium Capital, Bayer, Bioscience Managers, BioSeed Capital, Catapult Ventures, DeBere Capital Partners, FastVentures, Ignite Capital Partners, Industrifonden, INKEF Capital, Innovator Capital (ICL), Inventages Venture Capital, Investor Corporat, IPF Partners, Julz Co, Kreos Capital, M Ventures, Masselos Family Office, MEDICXI, Mercia Technologies, Momentum Biotech, National Institute for Health Research, NCL Technology Ventures, New Mosaic, New Science Fund, Norgine Ventures, Novo Seeds, Novo Ventures, Optum Ventures, Panakes Partners, Rothschild, Seroba Life Sciences, Seventure, Silicon Valley Bank, Sofinnova, Start Codon, Sunstone Life Science Ventures, UKI2S, Velocity Fund Partners, Vivanova
Delegates: Abbvie, Adenium Biotech, Antagonis Biotherapeutics, Artios Pharma, AstraZeneca, AVILLION, Bayer, BioPartner UK, Calliditas Therapeutics, CLS AB, Department for International Trade Sweden, Edwin Moses, Eli Lilly, Embassy of Spain in London, Ezenze, F2G, ImaginAB, Indi Molecular, Invest in Denmark, J A Kemp, Johnson and Johnson Innovation, Lavivo, London Business School, Medherant, Medicon Valley Alliance (MVA), MediSieve, Meeting Mojo, Mission Therapeutics, One Nucleus, Optimum Strategic Communications, Oxford Cardiomox, Parkinson's Concierge, PCI Clinical Services, PharmaKrysto Ltd, Public Health England, RDP Life Sciences, ReNeuron, RTC S.p.A., Sygnature Discovery, Virokine Therapeutics (VTL), Zerion.